250 related articles for article (PubMed ID: 32063381)
1. Neuropeptide galanin and its effects on metabolic and reproductive disturbances in female rats with estradiol valerate (EV) - Induced polycystic ovary syndrome (PCOS).
Azin F; Khazali H
Neuropeptides; 2020 Apr; 80():102026. PubMed ID: 32063381
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Determinants of Polycystic Ovary Syndrome.
Szeliga A; Rudnicka E; Maciejewska-Jeske M; Kucharski M; Kostrzak A; Hajbos M; Niwczyk O; Smolarczyk R; Meczekalski B
Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270780
[TBL] [Abstract][Full Text] [Related]
4. Galanin-like peptide and its correlation with androgen levels in patients with polycystic ovary syndrome.
Demirpence M; Yilmaz Yasar H; Karakoyun I; Girgin EM
Endokrynol Pol; 2023; 74(2):197-202. PubMed ID: 37155301
[TBL] [Abstract][Full Text] [Related]
5. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
Hohmann FP; Laven JS; Mulders AG; Oberyé JJ; Mannaerts BM; de Jong FH; Fauser BC
J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
Arroyo A; Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
[TBL] [Abstract][Full Text] [Related]
7. Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase.
Wang W; Zheng J; Cui N; Jiang L; Zhou H; Zhang D; Hao G
J Ovarian Res; 2019 Nov; 12(1):109. PubMed ID: 31722718
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
9. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
10. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Bakhshalizadeh S; Amidi F; Alleyassin A; Soleimani M; Shirazi R; Shabani Nashtaei M
Syst Biol Reprod Med; 2017 Jun; 63(3):150-161. PubMed ID: 28345956
[TBL] [Abstract][Full Text] [Related]
11. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models.
Roland AV; Moenter SM
Front Neuroendocrinol; 2014 Oct; 35(4):494-511. PubMed ID: 24747343
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Action of Virgin Coconut Oil and Clomiphene in Reversing Endocrine Dysregulation in Letrozole-Model of Polycystic Ovarian Syndrome in Rats: Role of Nrf2/HMOX-1 Pathway.
Ajibare AJ; Akintoye OO; Famurewa AC; Folawiyo MA; Bamisi OD; Asuku AO; Oyegbola OE; Akintayo CO; Olofinbiyi BA; Omotuyi OI
J Med Food; 2023 Sep; 26(9):683-691. PubMed ID: 38084993
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine control in polycystic ovary-like syndrome.
Schoemaker J
Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
[TBL] [Abstract][Full Text] [Related]
14. Regulation of gonadotropin subunit messenger ribonucleic acid expression in gonadotropin-releasing hormone (GnRH)-deficient female rats: effects of GnRH, galanin, GnRH-associated peptide, neuropeptide-Y, and thyrotropin-releasing hormone.
Kerrigan JR; Yasin M; Haisenleder DJ; Dalkin AC; Marshall JC
Biol Reprod; 1995 Jul; 53(1):1-7. PubMed ID: 7545437
[TBL] [Abstract][Full Text] [Related]
15. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
16. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
17. Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.
Qiu Z; Dong J; Xue C; Li X; Liu K; Liu B; Cheng J; Huang F
J Ethnopharmacol; 2020 Mar; 250():111965. PubMed ID: 31185267
[TBL] [Abstract][Full Text] [Related]
18. Activation of arcuate nucleus GABA neurons promotes luteinizing hormone secretion and reproductive dysfunction: Implications for polycystic ovary syndrome.
Silva MSB; Desroziers E; Hessler S; Prescott M; Coyle C; Herbison AE; Campbell RE
EBioMedicine; 2019 Jun; 44():582-596. PubMed ID: 31178425
[TBL] [Abstract][Full Text] [Related]
19. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.
Baskind NE; Balen AH
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():80-97. PubMed ID: 27137106
[TBL] [Abstract][Full Text] [Related]
20. Response of gonadotropins to pituitary stimulation with luteinizing hormone releasing hormone is a more specific than sensitive parameter for the polycystic ovary syndrome.
Steck T; Wernze H; Albert PJ
Gynecol Endocrinol; 1991 Dec; 5(4):235-47. PubMed ID: 1796746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
